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We report a case of a patient with CF who had a long history of recurrent distal intestinal obstruction syndrome. She had been treated with
conventional treatment including gastrografin, n-acetyl cysteine, Klean prep and Picolax.
She underwent a modified antegrade continence enema procedure. She currently irrigates her conduit every 2–3 days. She has had no
further symptoms of distal intestinal obstruction syndrome.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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A 17-year-old woman with cystic fibrosis presented to
the Leeds Adult Cystic Fibrosis Unit at regular intervals
with severe abdominal pain due to distal intestinal
obstruction syndrome (DIOS). Abdominal X-rays at the
time of presentation showed evidence of faecal loading in
the caecum and the ascending colon. She had been
diagnosed as having cystic fibrosis (CF) during the
neonatal period and genetic screening has shown her to
be homozygous for the DF508 mutation. She was born
with duodenal atresia and had a laparotomy for this
shortly after birth. She underwent a further laparotomy in
1997 for obstruction secondary to adhesions. During this
laparotomy she had adhesiolysis and an appendectomy.
Prior to a modified antegrade continence enema
(ACE) procedure, the patient’s height was 1.56 m,
weight 48.5 kg and body mass index (BMI) 19.9 kg/
m2. She was pancreatic insufficient and was taking
pancreatic enzyme replacement therapy in the form of
Creon 10000 (Solvay Healthcare). She was not diabetic,1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.06.008
* Corresponding author.had not received nasogastric or gastrostomy feeding, but
did take nutritional supplements orally as part of her
calorie intake.
Assessment of absorption was not carried out quanti-
tatively but faecal fat microscopy was negative for both
neutral and split fats. Faecal chymotrypsin was 633 mcg/g
(normalN120 mcg/g). This had improved from 3 years
previously when fat microscopy indicated neutral fat +++,
split fat +++. At this time faecal chymotrypsin was b60
mcg/g suggesting poor adherence to enzyme therapy.
Dietetic education was implemented at that time and she
had undergone regular review.
The reported dose of pancreatic enzyme replacement
therapy was less than 2100 IU lipase/kg/meal and approx-
imately 4800 IU lipase/kg/day, a level that is well within the
recommended range being neither excessively high nor low
for a patient of this age. In addition the patient was receiving
regular omeprazole (AstraZeneca) as an adjunct to enzyme
therapy.
The patient was chronically infected with Pseudomonas
aeruginosa and received regular courses of home and
hospital intravenous antibiotics. Her lung function was stable
with a baseline FEV1 and FVC of 1.63 L/s (56% predicted)
and 2.8 L (92% predicted), respectively.3 (2004) 273–275ed by Elsevier B.V. All rights reserved.
Fig. 1. Post surgery anatomy.
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for over 10 years but the frequency of admissions had
increased significantly. In February 2001 she presented with
DIOS that was successfully treated with both gastrografin
(Schering) orally and via enemas. Over the next few months
the patient had repeated admissions to hospital with
recurrent symptoms of DIOS. She was treated with gastro-
grafin (Schering), n-acetyl cysteine (Celltech), Klean Prep
(Norgine), and Picolax (Ferrings Pharmaceuticals). A
barium enema was undertaken which revealed no colonic
strictures or obstructing lesions. The patient was also started
on a low residue, low fat diet. In spite of all these
interventions the patient’s symptoms continued unabated.
Following extensive discussion with the patient and
counselling by the specialist stoma nurses, a modified ACE
procedure was undertaken in April 2002. The terminal ileum
was used to create the irrigation conduit. The proximal end
of the ileum was anastomosed to the ascending colon (Fig.
1). This was necessary as the patient’s appendix was
unavailable to be used as a conduit. If her appendix had
been present then a laproscopic ACE procedure could have
been undertaken. The patient made an unremarkable post-
operative recovery and was discharged home.
She is currently irrigating using tap water every 2–3 days
depending upon her dietary intake. Following irrigation she
has good bowel movements. The patient is currently making
good progress and has had no further episodes of DIOS.2. Discussion
DIOS develops in patients with CF due to the accumu-
lation of viscous mucous and faecal material in the terminal
ileum, caecum and ascending colon [1]. DIOS results in
symptoms of recurrent abdominal pain, bloating, nausea and
anorexia, and can lead to small intestine obstruction. The
incidence of DIOS in patients with CF is about 15% [2].
Initially DIOS was only described in pancreatic insufficient
patients with CF, however it has been since described in
patients with normal pancreatic function [3,4]. Approxi-
mately 11% of all patients with CF have no symptoms of
malabsorption [2].Conventional treatment of DIOS involves rehydration
(intravenous fluids if necessary) and the use of oral
gastrografin (Schering) [1]. Alternatively the intestines can
be flushed out using a balanced electrolyte solution such as
Klean-Prep (Norgine) [3] which may need to be given orally
or via a nasogastric tube. In the more severe case, DIOS can
be successfully treated using gastrografin (Schering) direc-
ted into the lumen of the ascending colon by means of either
an enema [1] or colonoscopy [5]. In a minority of patients
conventional therapy may fail and results in repeated
admissions, chronic abdominal symptoms and a reduction
in quality of life.
It has been suggested that the pro-kinetic drug, cisapride
(Janssen-Cilag) can be used to improve the symptoms of
chronic DIOS, although it does not abolish the need for
intestinal lavage [6]. The use of Cisapride (Janssen-Cilag)
has been discontinued in many CF centres following the
suspension of the product licence due to concern about
prolongation of the QT interval and ventricular arrhythmias.
A number of studies have suggested that DIOS occurs
more frequently in patients on inadequate pancreatic
enzyme replacement [7]. Assessment of pancreatic enzyme
therapy and knowledge of enzyme titration should be
assessed by an experienced CF dietitian [8]. This is essential
when patients present with recurring DIOS. Reduction of
gastric acid or acid suppression as a means of improving
enzyme efficacy with a proton pump inhibitor has been
reported and proton pump inhibitors are often used [7].
Faecal chymotrypsin is low in untreated pancreatic
insufficient patients with CF and can be useful for
monitoring enzyme therapy with low values suggesting
inadequate therapy possibly due to poor adherence [8].
Whilst levels had been low in this patient in the preceding
years there had been improvement in adherence to therapy
and the patient’s knowledge of enzyme titration through
education.
In addition to assessment of enzyme therapy, assessment
of malabsorption and/or steatorrhoea is valuable. The 72 h
faecal fat collection is the gold standard for assessing fat
absorption however faecal fat microscopy has been shown
as a useful tool to detect steatorrhoea [9]. Fat microscopy
shows some correlation between microscopic grading and
severity of steatorrhoea and has been validated by compar-
ison with quantitative measurements [10].
The ACE procedure was initially described for the
treatment of intractable constipation or faecal incontinence
in children [11,12]. It has since been used to treat adults
with both constipation and faecal incontinence [13]. The
underlying diseases that have necessitated an ACE proce-
dure include anorectal malformations, Hirschsprung’s dis-
ease, spina bifida, spinal injuries, severe perineal injury,
neuropathic disorders, cerebral palsy, and idiopathic con-
stipation [14]. The procedure involves bringing the appen-
dix out onto the abdominal wall to create a conduit resulting
in a small stoma. Modifications to the ACE procedure have
been undertaken where the appendix is not available using
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create the irrigation conduit [14]. In a retrospective review
of the ACE procedure using either ileum or appendix to
create the irrigation conduit there was no difference in
compliance or continence rates [15].
There is a possibility that the disruption of the ileo-caecal
valve by the modified ACE procedure is of importance in this
patient. The terminal ileum is important in the development
of DIOS. However in this patient the faecal material was in
the caecum and ascending colon. We feel that irrigation of the
terminal ileum via the conduit is unlikely, but the only way to
determine whether this occurs is to undertake a contrast study
which would involve radiation exposure to the patient and
would be of academic interest only.
To our knowledge this is the first report of a modified
ACE procedure being used for the treatment of DIOS in a
patient with cystic fibrosis. The procedure provides an
alternative approach when conventional treatment has been
unsuccessful or is not tolerated.References
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